Zydus Cadila gets USFDA nod for anti-hypertension drug

To market Telmisartan in the strengths of 20 mg, 40 mg and 80 mg

Ahmedabad-based pharma major Zydus Cadila has received the final approval from the US drug regulator to market Telmisartan tablets.

The company said in a statement today that it has received the nod from the US Food and Drug Administration (USFDA) to market the anti-hypertension tablets (Telmisartan) in the strengths of 20mg, 40mg and 80mg.  The estimated sales in 2014 for Telmisartan Tablets which fall in the anti-hypertensive segment is  $233.3 million, as per IMS, the company statement claimed.

The group now has 96 approvals and has so far filed 249 abbreviated new drug approvals (ANDAs) since the commencement of the filing process in fiscal 2003-04.

Earlier this month, the company had received approvals for marketing an anti-viral drug Acyclovir tablets and also one Potassium Citrate tablets which are used in the prevention of kidney stones. The company had said that the estimated sales for Acyclovir tablets in 2014 is $55.8 million.